NAFLD / MASLD
Also known as Non-alcoholic Fatty Liver Disease · Metabolic-dysfunction-Associated Steatotic Liver Disease
Fat accumulation in the liver driven by metabolic dysfunction — renamed MASLD in 2023 to reflect the central role of metabolism.
Definition
Non-alcoholic fatty liver disease, now termed metabolic-dysfunction-associated steatotic liver disease (MASLD), is the accumulation of fat in the liver without significant alcohol intake. Associated with visceral adiposity, insulin resistance and metabolic syndrome. The progressive form (MASH) can lead to fibrosis and cirrhosis. Tesamorelin has shown benefit in dedicated trials; GLP-1s and weight loss in general are the mainstay of treatment.
Read More
Tesamorelin
A stabilised GHRH analog with FDA approval for visceral-fat reduction in HIV-associated lipodystrophy — increasingly used off-label for metabolic syndrome.
Clinical ConceptMetabolic Syndrome
A cluster of five conditions — central obesity, hypertension, dyslipidaemia, hyperglycaemia, low HDL — that together multiply cardiovascular risk.
Clinical ConceptVisceral FatVisceral Adipose Tissue
Fat stored around internal organs — metabolically active, tied to cardiovascular risk, and the target of Tesamorelin and SCULPT.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.